insights_auto
Why is TNG down 6.17%?
Dive Deeperchevron_right
TNG:EPA
Transgene SA
€0.76
arrow_downward
-6.17%(-0.050) 1D
Sep 25, 5:35:13 PM GMT+2 · EUR
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for TNG...
Open
€0.81
High
€0.81
Low
€0.76
Mkt. cap
211.71M
Avg. vol.
146.80K
Volume
201.75K
52-wk high
€1.50
52-wk low
€0.70
EPS
-€0.26
Shares outstanding
278.56M
No. of employees
145
Open
€0.81
High
€0.81
Low
€0.76
Mkt. cap
211.71M
Avg. vol.
146.80K
Volume
201.75K
52-wk high
€1.50
52-wk low
€0.70
EPS
-€0.26
Shares outstanding
278.56M
No. of employees
145
News stories
From web sources and news partners
TipRanks
·
1 day ago
Transgene Advances myvac® Cancer Vaccines and MVA Platform With Cash Runway to 2028
www.marketscreener.com
·
1 day ago
Availability of Transgene’s Half-Year Financial Report as of June 30, 2026
Profile
Transgene S.A. is a French biotechnology company founded in 1979. It is based in Illkirch-Graffenstaden, near Strasbourg, Alsace. The company develops and manufactures immunotherapies for the treatment of cancer. Based on viral vectors, these therapies stimulate the immune defenses of patients to specifically target cancer cells.
Transgene has two technological platforms based on these respective approaches: individual therapeutic vaccines, shared antigens cancer vaccines oncolytic viruses.
Transgene's portfolio consists of four products currently in clinical development. Its lead product TG4050, a neoantigen individualized therapeutic cancer vaccine is currently being developed in a randomized Phase I/II trial in the adjuvant treatment of head and neck cancer.
The company is listed on the regulated market of Euronext in Paris. Wikipedia
About Transgene SA